Skip to main content
Delta-Fly Pharma, Inc. logo

Delta-Fly Pharma, Inc. — Investor Relations & Filings

Ticker · 4598 ISIN · JP3549370009 T Professional, scientific and technical activities
Open in API
Filings indexed 63 across all filing types
Latest filing 2019-06-24 Annual Report
Country JP Japan
Listing T 4598

About Delta-Fly Pharma, Inc.

https://www.delta-flypharma.co.jp/en/

Delta-Fly Pharma, Inc. is a biopharmaceutical company specializing in the research and development of anticancer drugs. The company's core strategy is its proprietary "Module Drug Development" concept, an approach that combines existing pharmaceutical components to create novel therapeutic agents. This methodology aims to develop effective cancer treatments with significantly reduced side effects and at reasonable prices, thereby improving the quality of life for patients. The company's pipeline includes several drug candidates for various cancers, with some, such as DFP-10917 for refractory/relapsed acute myeloid leukemia, advancing to late-stage clinical trials. Delta-Fly Pharma focuses on creating gentle yet potent therapies, including nucleoside analogs and RNA therapeutics.

Recent filings

Filing Released Lang Actions
有価証券報告書－第9期(平成30年4月1日－平成31年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which translates to 'Annual Securities Report'. This is the standard, comprehensive annual financial filing required by the Financial Services Agency of Japan under the Financial Instruments and Exchange Act. It contains detailed financial statements, business descriptions, and management analysis for the fiscal year ending March 31, 2019. It is not an announcement or a summary, but the full report itself. FY 2019
2019-06-24 Japanese
四半期報告書－第9期第3四半期(2018/10/01－2018/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Delta-Fly Pharma, Inc., covering the third quarter of the fiscal year ending March 31, 2019. It contains detailed financial statements (balance sheet, income statement), management analysis of financial results, and information on share capital. It is a formal regulatory filing submitted to the Shikoku Finance Bureau under the Financial Instruments and Exchange Act. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. 9M 2019
2019-02-14 Japanese
四半期報告書－第9期第2四半期(2018/07/01－2018/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Delta-Fly Pharma, Inc., covering the period from April 1, 2018, to September 30, 2018. It contains detailed financial statements, including the balance sheet, income statement, and cash flow statement, as well as management analysis and notes. It is a formal regulatory filing submitted to the Shikoku Finance Bureau under the Financial Instruments and Exchange Act. As it provides comprehensive financial data for an interim period, it is classified as an Interim/Quarterly Report. Q2 2018
2018-11-14 Japanese

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.